NCT06231212 (TMD ECa233) is a Phase 2, PHASE3 clinical trial of ECa 233 in Temporomandibular Disorder, sponsored by Chulalongkorn University.

Who is sponsoring NCT06231212?

NCT06231212 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT06231212?

Interventions in NCT06231212: ECa 233, Ibuprofen, Placebo.

What condition does NCT06231212 study?

NCT06231212 studies Temporomandibular Disorder.

Is NCT06231212 still recruiting?

NCT06231212 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT06231212: TMD ECa233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder

Completed Phase 2, PHASE3 Last updated 7 February 2024

What this trial tests

Phase 2, PHASE3 trial testing ECa 233 in Temporomandibular Disorder in 23 participants. Completed in 30 December 2022.

Timeline

5 August 2020

Primary endpoint
1 September 2021

30 December 2022

Quick facts

Lead sponsor	Chulalongkorn University
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	triple
Primary purpose	treatment
Enrollment	23
Start date	5 August 2020
Primary completion	1 September 2021
Estimated completion	30 December 2022
Sites	1 location across Thailand

Drugs / interventions tested

ECa 233 — full drug profile →
Ibuprofen (ibuprofen) — full drug profile →
Placebo

Conditions studied

Temporomandibular Disorder — all drugs for Temporomandibular Disorder →

Sponsor

Chulalongkorn University

Who can join

Adults 18 to 55, any sex, with Temporomandibular Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test analgesic effect of ECa 233 in subjects with TMD. The main questions it aims to answer are: * Can ECa 233 reduce pain intensity score in subjects with acute TMD? * Can ECa 233 increase jaw functional movements in subjects with acute TMD? Participants will be separated into four groups, including placebo, ibuprofen, low-dosed Eca and high-dosed Eca groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of Centella asiatica on mitigating temporomandibular pain and improving functionality: a randomized, double blind, pilot clinical trial.
Potewiratnanond P, Surarit R, Tantisira MH, Samaranayake L, et al · · 2025 · PMID 40253389 · DOI 10.1186/s13005-025-00503-y

Verify or expand the search:

Other recruiting trials for Temporomandibular Disorder

Currently open trials in the same condition.

NCT06941636 — Botulinumtoxin A as a Treatment for Myalgia and Myofacial Pain in Patient With Temporomandibulardisorders · Phase 3 · recruiting
NCT03849534 — Treatment of Temporomandibular Disorders in Children and Adolsecents · NA · recruiting
NCT06214923 — Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG) · NA · recruiting
NCT06365151 — An Algorithm for Approaching Temporomandibular Disorders With Osteopathic Manual Therapy in Patients With Fibromyalgia · NA · recruiting
NCT06357702 — K23- Physical Self Regulation vs Placebo · NA · recruiting

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06231212 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing